Related Experiment Video

Updated: Sep 23, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

FAK PROTAC Inhibits Ovarian Tumor Growth and Metastasis by Disrupting Kinase Dependent and Independent Pathways

Xueyun Huo1,2,3, Wenjing Zhang4, Guannan Zhao2,3

  • 1School of Basic Medical Sciences, Capital Medical University, Beijing, China.

Frontiers in Oncology
|May 16, 2022
PubMed

Insights

A novel drug, FAK PROTAC, effectively targets both kinase and scaffold functions of focal adhesion kinase (FAK) in ovarian cancer. This dual action significantly inhibits tumor growth and metastasis, outperforming existing FAK inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Focal adhesion kinase (FAK) is crucial in various cancers, but existing inhibitors targeting only its kinase activity show limited clinical efficacy.
  • FAK also acts as a scaffold protein, mediating kinase-independent pathways essential for cancer progression.

Purpose of the Study:

  • To evaluate the therapeutic potential of FAK PROTAC, a novel drug designed to inhibit both FAK kinase and scaffold activities, for ovarian cancer treatment.
  • To compare the efficacy of FAK PROTAC against its parent kinase inhibitor, VS-6063, in preclinical ovarian cancer models.

Main Methods:

  • In vitro assays assessed cell proliferation, migration, and invasion in ovarian cancer cell lines treated with FAK PROTAC and VS-6063.
  • In vivo studies utilized orthotopic ovarian cancer mouse models to evaluate tumor growth and metastasis.
  • Molecular analyses investigated FAK PROTAC's impact on kinase-dependent and -independent pathways, including FAK-ASAP1 interactions.

Main Results:

  • FAK PROTAC demonstrated superior efficacy over VS-6063 in inhibiting ovarian cancer cell proliferation, survival, migration, and invasion.
  • FAK PROTAC successfully disrupted both FAK's kinase activity and its scaffold function by preventing FAK-ASAP1 complex formation.
  • FAK PROTAC significantly suppressed ovarian tumor growth and metastasis in vivo.

Conclusions:

  • FAK PROTAC represents a promising therapeutic strategy for ovarian cancer by simultaneously inhibiting FAK's kinase and scaffold functions.
  • Targeting both FAK pathways with FAK PROTAC offers a more effective approach to controlling ovarian tumor progression and metastasis.
Keywords:
ASAP1FAK PROTACfocal adhesion kinase (FAK)metastasisovarian cancer

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.4K
A Proximal Culture Method to Study Paracrine Signaling Between Cells08:17

A Proximal Culture Method to Study Paracrine Signaling Between Cells

Published on: August 28, 2018

9.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K